Last reviewed · How we verify

Cosentyx — Competitive Intelligence Brief

Cosentyx (secukinumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-17A antagonist. Area: Immunology.

marketed IL-17A antagonist Interleukin-17A (IL-17A) Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Cosentyx (secukinumab) — Novartis. Secukinumab selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cosentyx TARGET secukinumab Novartis marketed IL-17A antagonist Interleukin-17A (IL-17A) 2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-17A antagonist class)

  1. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cosentyx — Competitive Intelligence Brief. https://druglandscape.com/ci/secukinumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: